Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kate Rawson

Kate Rawson is a Contributing Editor at Prevision Policy. She was a Senior Editor at The RPM Report and reporter and editor at The Pink Sheet where she covered drug regulation and reimbursement issues. During her ten-year tenure at FDC Reports, she helped launch The Pink Sheet DAILY, and also served as Managing Editor of The Rose Sheet, which covers regulatory and business news of the cosmetics industry.

Latest From Kate Rawson

US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’

Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.

Diagnostics Regulation

Drug-Drug Interactions: Future FDA Guidance Will Focus On Specific Modalities; Patient Website To Come

US FDA took ‘broadest’ approach possible with initial guidance on drug-drug interactions; additional documents will dive into issues specific to different therapeutic areas. But PK/PD modeling and AI alternatives will have to wait.

Guidance Documents Drug Approval Standards

US FDA Regulatory Affairs Reorg To Include Inspectors Trained In Real-World Evidence, Califf Says

The US FDA Commissioner acknowledged that the inspectorate has not been prepared for RWE, but as part of the revamp, a dedicated team will encourage its use “when it’s appropriate.”

Real-World Evidence Review Pathway

US FDA Regulatory Affairs Reorg To Include Inspectors Trained In Real-World Evidence, Califf Says

The US FDA Commissioner acknowledged that the inspectorate has not been prepared for RWE, but as part of the revamp, a dedicated team will encourage its use “when it’s appropriate.”

Real-World Evidence Review Pathway

US FDA Regulatory Affairs Reorg To Include Inspectors Trained In Real-World Evidence – Califf

The US FDA Commissioner acknowledged that the inspectorate has not been prepared for RWE, but as part of the revamp, a dedicated team will encourage its use “when it’s appropriate.”

Real-World Evidence FDA

Cell/Gene Therapy Is Ripe For Real-World Data Given Length Of Follow-Up Required, Abernethy Says

The former principal deputy commissioner outlined what she sees as the future data requirements for real world evidence and why cell and gene therapy will lead the way.

Gene Therapy Real-World Evidence
See All
UsernamePublicRestriction

Register